Bernstein said it had learned that Novartis' generic Sandoz division was setting prices and soliciting pre-orders from U.S. purchasers for its generic form of Lovenox, or enoxaparin.
Agree on NVS not issuing any such statements per se...however could it be that Bernstien conveyed a hightened sense of such 'activity' which market seems to be inferring as approval being imminent ?
It's bit intriguing that Bernstien could or would not comment on MNTA getting the sole approval or not, assuming his information is more than just stemming from inference.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.